Related Experiment Video
Updated: May 24, 2025
Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
Published on: February 2, 2013
Agent-based modeling of cellular dynamics in adoptive cell therapy
Yujia Wang1, Stefano Casarin2,3,4, May Daher5
1Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
Adoptive cell therapies (ACT) leverage tumor-immune interactions to cure cancer. Despite promising phase I/II clinical trials of chimeric-antigen-receptor natural killer (CAR-NK) cell therapies, molecular mechanisms and cellular properties required to achieve clinical benefits in broad cancer spectra remain underexplored. While in vitro and in vivo experiments are required in this endeavor, they are typically expensive, laborious, and limited to targeted investigations. Here, we present ABMACT (Agent-Based Model for Adoptive Cell Therapy), an in silico approach employing agent-based models (ABM) to simulate the continuous course and dynamics of an evolving tumor-immune ecosystem, consisting of heterogeneous "virtual cells" created based on knowledge and omics data observed in experiments and patients. Applying ABMACT in multiple therapeutic context indicates that to achieve optimal ACT efficacy, it is key to enhance immune cellular proliferation, cytotoxicity, and serial killing capacity. With ABMACT, in silico trials can be performed systematically to inform ACT product development and predict optimal treatment strategies.
Insights
This study introduces ABMACT, a computational model for adoptive cell therapy (ACT). It simulates tumor-immune dynamics to identify key strategies for enhancing cancer treatment efficacy.
Area of Science:
- Immunology
- Computational Biology
- Cancer Research
Background:
- Adoptive cell therapies (ACT) show promise for cancer treatment by harnessing tumor-immune interactions.
- Understanding the molecular mechanisms and cellular properties driving clinical success in chimeric-antigen-receptor natural killer (CAR-NK) cell therapies remains crucial.
- Current experimental models (in vitro, in vivo) are costly, labor-intensive, and limited in scope.
Purpose of the Study:
- To develop an in silico approach for simulating tumor-immune ecosystem dynamics in adoptive cell therapy.
- To identify critical cellular properties and therapeutic strategies for enhancing ACT efficacy across diverse cancers.
- To provide a platform for systematic in silico trials to guide ACT product development.
Main Methods:
- Development of ABMACT (Agent-Based Model for Adoptive Cell Therapy), an agent-based modeling (ABM) framework.
- Simulation of heterogeneous tumor-immune ecosystems using virtual cells based on experimental and patient omics data.
- Application of the model in various therapeutic contexts to analyze ACT dynamics.
Main Results:
- The study identified key factors for optimal ACT efficacy: enhanced immune cellular proliferation, cytotoxicity, and serial killing capacity.
- ABMACT successfully simulated the continuous course and dynamics of evolving tumor-immune interactions.
- In silico trials demonstrated the model's utility in predicting treatment outcomes.
Conclusions:
- ABMACT offers a powerful computational tool to explore complex tumor-immune dynamics in ACT.
- The model can systematically inform ACT product development and predict optimal treatment strategies.
- Enhancing specific immune cell functions is critical for maximizing the clinical benefits of adoptive cell therapies.
